PTLD
MCID: PST046
MIFTS: 58

Post-Transplant Lymphoproliferative Disease (PTLD)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

MalaCards integrated aliases for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 38 53 59
Post-Transplant Lymphoproliferative Disorder 73
Ptld 59

Characteristics:

Orphanet epidemiological data:

59
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

Orphanet 59 ORPHA70568
UMLS via Orphanet 74 C0432487
ICD10 via Orphanet 34 D47.9
UMLS 73 C0432487

Summaries for Post-Transplant Lymphoproliferative Disease

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to hematopoietic stem cell transplantation and hemophagocytic lymphohistiocytosis. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cyclophosphamide and rituximab have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 30.7 IL10 IL6 TNF
2 hemophagocytic lymphohistiocytosis 30.1 B2M IL10 TNF
3 viral infectious disease 30.1 IL10 IL6 TNF
4 pneumonia 30.0 IL10 IL6 TNF
5 toxoplasmosis 30.0 IL10 IL6 TNF
6 graft-versus-host disease 29.9 IL10 IL1A IL6 TNF
7 myeloma, multiple 29.8 B2M CASP8 IL6 TNF
8 lyme disease 11.3
9 autoimmune lymphoproliferative syndrome, type v 10.5
10 lymphoproliferative syndrome 10.5
11 lymphoma 10.4
12 funisitis 10.3 IL10 IL6
13 scabies 10.3 IL10 IL1A
14 extramedullary plasmacytoma 10.3 B2M IL6
15 cow milk allergy 10.2 IL10 TNF
16 trichuriasis 10.2 IL10 TNF
17 mucocutaneous leishmaniasis 10.2 IL10 TNF
18 inflammatory bowel disease 25, autosomal recessive 10.2 IL10 IL10RA
19 aids dementia complex 10.2 B2M TNF
20 retinitis pigmentosa 55 10.2 IL6 TNF
21 glossitis 10.2 IL6 TNF
22 laryngitis 10.2 IL6 TNF
23 anca-associated vasculitis 10.2 IL6 TNF
24 cardiogenic shock 10.2 IL6 TNF
25 skin conditions 10.2 IL1A TNF
26 punctate inner choroidopathy 10.2 IL10 TNF
27 vulvar vestibulitis syndrome 10.2 IL1R1 TNF
28 tropical endomyocardial fibrosis 10.2 IL10 TNF
29 endomyocardial fibrosis 10.2 IL10 TNF
30 hepatitis 10.2
31 extrapulmonary tuberculosis 10.2 IL10 IL10RA SLC11A1
32 familial cold autoinflammatory syndrome 1 10.1 IL1R1 TNFRSF1A
33 eye lymphoma 10.1 IL10 IL6
34 scorpion envenomation 10.1 IL6 TNF
35 radiculopathy 10.1 IL1A IL1R1 IL6
36 microscopic polyangiitis 10.1 IL10 TNF
37 leukomalacia 10.1 IL6 TNF
38 nervous system disease 10.1 IL10 IL6 TNF
39 multifocal choroiditis 10.1 IL10 TNF
40 choroiditis 10.1 IL10 TNF
41 angioimmunoblastic lymphadenopathy with dysproteinemia 10.1 IL6 TNF
42 autoimmune gastritis 10.1 IL10 IL6 TNF
43 autoimmune disease of eyes, ear, nose and throat 10.1 IL10 IL6 TNF
44 intermediate uveitis 10.1 IL10 IL6 TNF
45 transverse myelitis 10.1 IL10 IL6 TNF
46 mycoplasma pneumoniae pneumonia 10.1 IL10 IL6 TNF
47 eales disease 10.1 IL10 IL6 TNF
48 meningitis 10.1 IL10 IL6 TNF
49 chronic graft versus host disease 10.1 IL10 IL1A TNF
50 acute transverse myelitis 10.1 IL10 IL6

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 CASP8 FADD IL10 IL1A LTA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 CASP8 FADD IL10 IL1A LTA TNF

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 B2M CASP8 FADD IL10 IL10RA IL1A
2 cardiovascular system MP:0005385 10.35 B2M CASP8 FADD IL10 IL1A IL1R1
3 immune system MP:0005387 10.35 B2M CASP8 FADD IL10 IL10RA IL1A
4 homeostasis/metabolism MP:0005376 10.34 B2M CASP8 FADD IL10 IL10RA IL1A
5 endocrine/exocrine gland MP:0005379 10.31 B2M CASP8 FADD IL10 IL1R1 IL6
6 cellular MP:0005384 10.3 B2M CASP8 FADD IL10 IL10RA IL1R1
7 growth/size/body region MP:0005378 10.22 B2M CASP8 FADD IL10 IL1R1 IL6
8 mortality/aging MP:0010768 10.22 B2M CASP8 FADD IL10 IL1R1 IL6
9 digestive/alimentary MP:0005381 10.2 B2M FADD IL10 IL10RA IL6 SLC11A1
10 liver/biliary system MP:0005370 10.17 B2M CASP8 FADD IL10 IL1R1 IL6
11 integument MP:0010771 10.11 B2M CASP8 IL10 IL1A IL1R1 IL6
12 neoplasm MP:0002006 10.1 B2M CASP8 IL10 IL1A IL1R1 IL6
13 muscle MP:0005369 9.97 CASP8 FADD IL10 IL1R1 IL6 TNF
14 nervous system MP:0003631 9.96 B2M CASP8 FADD IL10 IL1R1 IL6
15 respiratory system MP:0005388 9.76 CASP8 IL10 IL1R1 IL6 LTA TNF
16 skeleton MP:0005390 9.61 FADD IL10 IL1R1 IL6 LTA TNF
17 vision/eye MP:0005391 9.17 IL10 IL1R1 IL6 LTA TNF TNFRSF1A

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2 6055-19-2, 50-18-0 2907
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
4
Vidarabine Approved, Investigational Phase 4,Phase 2,Phase 1 24356-66-9 32326 21704
5
Doxorubicin Approved, Investigational Phase 4,Phase 2 23214-92-8 31703
6
Fludarabine Approved Phase 4,Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
7
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
8
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
9
Doxil Approved June 1999 Phase 4,Phase 2 31703
10 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
11 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Alkylating Agents Phase 4,Phase 2,Phase 1
13 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Antiviral Agents Phase 4,Phase 2,Phase 1
18 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
20 Topoisomerase Inhibitors Phase 4,Phase 2
21 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
22 Liver Extracts Phase 4,Phase 2,Phase 3,Not Applicable
23 Calcineurin Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antitubercular Agents Phase 4,Phase 2,Phase 1
25
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
26
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
28
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
29
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
30
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
31
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
32
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
33
Pancrelipase Approved, Investigational Phase 3,Phase 2 53608-75-6
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
35
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1 2920-86-7
36 Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
38 Hormones Phase 2, Phase 3,Phase 3,Phase 1
39 Methylprednisolone acetate Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 3,Phase 2,Phase 1
42 Prednisolone acetate Phase 3,Phase 2,Phase 1
43 glucocorticoids Phase 3,Phase 2,Phase 1
44 Antiemetics Phase 3,Phase 2,Phase 1
45 Protective Agents Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
47 Neuroprotective Agents Phase 3,Phase 2,Phase 1
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
50 Adjuvants, Immunologic Phase 2, Phase 3

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
2 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
3 Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation Unknown status NCT00033475 Phase 3
4 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
5 Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab Recruiting NCT03392142 Phase 3
6 Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
7 To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids Not yet recruiting NCT03371667 Phase 3 Methotrexate;Placebo
8 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation Unknown status NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
9 Bortezomib Plus Rituximab for EBV+ PTLD Completed NCT01058239 Phase 2 bortezomib;rituximab
10 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
11 Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Completed NCT01964755 Phase 2 Doxorubicin;Methotrexate;Leucovorin;Zidovudine;Rituximab
12 Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Completed NCT00307125 Phase 2 Rituximab plus immunosuppression;Placebo plus immunosuppression
13 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Completed NCT01565616 Phase 2 Conditioning Regimen with Bone Marrow Transplant
14 Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy Recruiting NCT02042391 Phase 2 Rituximab sc;Rituximab sc consolidation;Rituximab sc combined with CHOP chemotherapy;Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
15 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder Recruiting NCT02900976 Phase 2
16 Tocilizumab in Cardiac Transplantation Recruiting NCT03644667 Phase 2 Standard of Care Triple IS
17 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas Terminated NCT02763254 Phase 2
18 Donor Lymphocyte Infusion After Alternative Donor Transplantation Terminated NCT01027702 Phase 1, Phase 2
19 Pilot Study of Unrelated Cord Blood Transplantation Terminated NCT00916045 Phase 2 Thiotepa;Fludarabine;Intravenous busulphan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Cyclophosphamide;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Melphalan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF)
20 Multi-Drug Desensitization Protocol for Heart Transplant Candidates Terminated NCT01556347 Phase 2 Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
21 Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation Terminated NCT01790594 Phase 2 methylprednisolone;Tacrolimus;Mycophenolate mofetil
22 Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease Recruiting NCT02867800 Phase 1 Diphenhydramine;Acetaminophen;Methylprednisolone;Meperidine;Alemtuzumab;Thymoglobulin;Fludarabine;Melphalan;Thiotepa;Cyclosporine;Tacrolimus;Methotrexate;Abatacept;Sirolimus;Mycophenolate Mofetil
23 Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Terminated NCT00087009 Phase 1
24 Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs Unknown status NCT00947492 Not Applicable
25 Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients Unknown status NCT02505789
26 Virus Surveillance in Pediatric Solid Organ Transplant Recipients Unknown status NCT00886158
27 Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients Completed NCT01375127 Tofacitinib;Tofacitinib
28 MMF After Pediatric Liver Transplantation Completed NCT00367146 Not Applicable MMF
29 Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists Completed NCT00859131 Not Applicable Rabbit Antithymocyte globulin;Daclizumab
30 Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03343834 Not Applicable
31 HLA-Identical Sibling Renal Transplant Tolerance Active, not recruiting NCT00619528 Not Applicable
32 Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant Not yet recruiting NCT03131934 Early Phase 1
33 Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study) Not yet recruiting NCT03802773
34 Relationship Between EBV and PTLD Terminated NCT00215033

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

41
Liver, B Cells, T Cells, Kidney, Heart, Bone, Lung

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 462)
# Title Authors Year
1
Post-transplant lymphoproliferative disease after liver transplantation. ( 29313699 )
2018
2
Post-transplant lymphoproliferative disease with features of cutaneous natural killer/T-cell lymphoma. ( 29380362 )
2018
3
Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. ( 29342279 )
2018
4
Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. ( 29071779 )
2018
5
Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. ( 29949208 )
2018
6
Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia. ( 30046412 )
2018
7
Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. ( 29797086 )
2018
8
A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy. ( 29755021 )
2018
9
Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. ( 30417487 )
2018
10
High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: A case report. ( 30362229 )
2018
11
Ectopic jejunal pancreas with pancreatitis mistaken for a post-transplant lymphoproliferative disease in an immunosuppressed kidney transplant patient. ( 30310646 )
2018
12
Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. ( 30173897 )
2018
13
Primary central nervous system post-transplant lymphoproliferative disorder mimicking toxoplasmosis. ( 30231131 )
2018
14
Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall. ( 29380181 )
2018
15
Reply to: Role of PET-CT in management of post-transplant lymphoproliferative disorder: Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder. ( 29077252 )
2018
16
A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. ( 29094407 )
2018
17
Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. ( 29114932 )
2018
18
Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases. ( 29188583 )
2018
19
Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. ( 29252057 )
2018
20
Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children. ( 29388302 )
2018
21
Post-transplant lymphoproliferative disorder prevention: new light on the horizon? ( 29432665 )
2018
22
Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Diagnosed by Peripheral Facial Nerve Palsy. ( 29434151 )
2018
23
Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients. ( 29517815 )
2018
24
Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder. ( 29580864 )
2018
25
Post-transplant lymphoproliferative disorder of the bladder in a lung transplant recipient. ( 29593873 )
2018
26
Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts: A case report and literature review. ( 29703027 )
2018
27
Increased Incidence of Post-transplant Lymphoproliferative Disorder in Autoimmune Liver Disease: An Irish National Experience. ( 29743796 )
2018
28
Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. ( 29745058 )
2018
29
Treatment of pediatric plasma cell myeloma type post-transplant lymphoproliferative disorder with modern risk-directed therapy. ( 29893485 )
2018
30
Pediatric cutaneous T-cell post-transplant lymphoproliferative disorder: Case report and review of the literature. ( 30054921 )
2018
31
Post-transplant lymphoproliferative disorder presenting on post-transplant Day 35 as a pulmonary parenchymal infiltrate-a case report. ( 30109030 )
2018
32
Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. ( 30327178 )
2018
33
Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. ( 30345623 )
2018
34
Post-transplant lymphoproliferative disorder of the cauda equina in a kidney transplant recipient. ( 30416756 )
2018
35
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis. ( 30447925 )
2018
36
Corrigendum to: Post-transplant lymphoproliferative disorder presenting on post-transplant Day 35 as a pulmonary parenchymal infiltrate-a case report. ( 30538820 )
2018
37
Immunotherapy with the trifunctional anti-CD20a88A9a88anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. ( 28093004 )
2017
38
Post-transplant lymphoproliferative disease in liver transplant recipients. ( 28508661 )
2017
39
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
40
Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. ( 28780922 )
2017
41
Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. ( 28906028 )
2017
42
Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. ( 28383790 )
2017
43
Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis. ( 27796825 )
2017
44
EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system. ( 28984115 )
2017
45
Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. ( 29075059 )
2017
46
High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature. ( 28717085 )
2017
47
Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective-a single centre experience. ( 26926524 )
2017
48
Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy. ( 27334275 )
2017
49
Post-transplant lymphoproliferative disorder: a heterogeneous conundrum. ( 27448018 )
2017
50
Post-transplant lymphoproliferative disorder: a heterogeneous conundrum - response to Weisenburger DD & Gross TG. ( 27471184 )
2017

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 B2M CASP8 FADD IL10 IL10RA IL1A
2
Show member pathways
13.88 CASP8 FADD IL6 LTA TNF TNFRSF10A
3
Show member pathways
13.86 CASP8 FADD IL10 IL10RA IL1A IL1R1
4
Show member pathways
13.7 CASP8 IL10 IL10RA IL1A IL1R1 IL6
5
Show member pathways
13.58 IL10 IL10RA IL1A IL1R1 IL6 LTA
6
Show member pathways
13.42 B2M IL10 IL10RA IL1A IL1R1 IL6
7
Show member pathways
13.36 FADD IL10 IL10RA IL1A IL1R1 IL6
8
Show member pathways
13.13 B2M CASP8 FADD IL10RA IL1R1 IL6
9
Show member pathways
13.1 CASP8 IL10 IL10RA IL1A IL1R1 IL6
10
Show member pathways
13.05 CASP8 FADD IL10 IL6 TNF TNFRSF1A
11
Show member pathways
13.03 CASP8 FADD IL6 LTA TNF TNFRSF10A
12
Show member pathways
13 CASP8 FADD IL6 TNF TNFRSF1A
13
Show member pathways
13 CASP8 FADD LTA TNF TNFRSF10A TNFRSF1A
14
Show member pathways
12.85 CASP8 FADD IL1R1 LTA TNF TNFRSF10A
15
Show member pathways
12.82 IL6 LTA TNF TNFRSF1A TNFRSF1B
16
Show member pathways
12.82 CASP8 FADD IL1A IL6 LTA TNF
17 12.81 CASP8 IL1A IL1R1 TNF TNFRSF1A
18
Show member pathways
12.78 FADD IL1A IL1R1 IL6 LTA TNF
19
Show member pathways
12.77 CASP8 IL1A IL1R1 LTA TNF TNFRSF1A
20
Show member pathways
12.72 CASP8 FADD IL1R1 TNFRSF10A TNFSF10
21
Show member pathways
12.68 IL10 IL10RA TNF TNFRSF1A TNFRSF1B
22
Show member pathways
12.65 IL10 IL1A IL1R1 IL6 TNF
23 12.62 B2M IL10 TNF TNFRSF1A TNFRSF1B
24
Show member pathways
12.6 IL10 IL10RA IL6 TNF
25
Show member pathways
12.59 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
26 12.49 IL1R1 IL6 LTA TNF TNFRSF1A
27
Show member pathways
12.46 IL10 IL1A IL6 TNF
28
Show member pathways
12.44 B2M CASP8 FADD IL10 IL10RA IL1A
29
Show member pathways
12.42 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
30
Show member pathways
12.39 CASP8 FADD IL1A IL1R1 LTA TNF
31
Show member pathways
12.38 CASP8 FADD IL6 TNF
32 12.37 B2M CASP8 FADD IL6 TNF
33
Show member pathways
12.37 CASP8 IL10 IL10RA IL1A TNF TNFRSF1A
34
Show member pathways
12.35 IL1A IL1R1 IL6 TNF
35
Show member pathways
12.35 CASP8 FADD TNFRSF10A TNFSF10
36
Show member pathways
12.34 CASP8 FADD IL1A TNF TNFRSF1A
37 12.34 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
38
Show member pathways
12.32 IL10 IL1A IL6 LTA TNF
39
Show member pathways
12.29 CASP8 FADD IL1A TNF TNFRSF10A TNFRSF1A
40
Show member pathways
12.28 IL1A IL1R1 IL6 TNF
41
Show member pathways
12.27 CASP8 IL10 IL6 TNF
42 12.24 IL10 IL1A IL6 TNF
43
Show member pathways
12.18 CASP8 FADD TNF TNFRSF1A
44 12.18 CASP8 FADD IL10 IL10RA IL1A IL6
45
Show member pathways
12.17 IL10 IL1R1 IL6 LTA TNF
46 12.16 IL1A IL1R1 TNF TNFRSF1A
47 12.11 IL1A IL1R1 TNF TNFRSF1A
48 12.1 IL10 IL1A IL6 TNF TNFRSF1B
49
Show member pathways
12.09 CASP8 FADD TNF TNFRSF1A
50 12.08 IL1A IL1R1 IL6 TNF

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 B2M IL10 IL1A IL6 LTA TNF
2 cell surface GO:0009986 9.85 B2M IL1R1 TNF TNFRSF10A TNFRSF1A
3 death-inducing signaling complex GO:0031264 9.4 CASP8 FADD
4 CD95 death-inducing signaling complex GO:0031265 9.37 CASP8 FADD
5 membrane raft GO:0045121 9.35 CASP8 FADD TNF TNFRSF1A TNFRSF1B
6 ripoptosome GO:0097342 9.32 CASP8 FADD
7 extracellular region GO:0005576 9.32 B2M IL10 IL1A IL1R1 IL6 LTA
8 tumor necrosis factor receptor superfamily complex GO:0002947 9.16 TNFRSF1A TNFRSF1B
9 plasma membrane GO:0005886 10.17 B2M FADD IL10RA IL1R1 LTA SLC11A1

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 IL10 SLC11A1 TNF TNFRSF1A
2 cell surface receptor signaling pathway GO:0007166 9.98 CASP8 FADD IL1R1 TNFRSF10A TNFRSF1A TNFRSF1B
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.96 CASP8 FADD TNF TNFRSF1A TNFSF10
4 cellular response to lipopolysaccharide GO:0071222 9.95 IL10 IL6 TNF TNFRSF1B
5 response to lipopolysaccharide GO:0032496 9.95 CASP8 IL10 IL10RA LTA SLC11A1 TNFRSF1B
6 inflammatory response GO:0006954 9.92 IL10 IL1A IL1R1 IL6 SLC11A1 TNF
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.89 IL10 IL6 TNF
8 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.89 CASP8 FADD TNF TNFRSF10A TNFSF10
9 negative regulation of inflammatory response GO:0050728 9.88 IL10 TNFRSF1A TNFRSF1B
10 defense response to Gram-positive bacterium GO:0050830 9.88 IL6 LTA TNF
11 cellular response to mechanical stimulus GO:0071260 9.88 CASP8 FADD TNFRSF10A TNFRSF1A
12 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 LTA TNF TNFRSF1A TNFRSF1B
13 response to glucocorticoid GO:0051384 9.86 IL10 IL6 TNF
14 apoptotic signaling pathway GO:0097190 9.85 CASP8 FADD TNF
15 humoral immune response GO:0006959 9.84 IL6 LTA TNF
16 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.84 CASP8 FADD TNFRSF10A TNFSF10
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.83 TNF TNFRSF1A TNFRSF1B
18 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.8 CASP8 TNF TNFRSF1A
19 extrinsic apoptotic signaling pathway GO:0097191 9.8 CASP8 FADD TNF TNFRSF10A TNFRSF1B
20 positive regulation of cytokine secretion GO:0050715 9.79 IL10 IL1A TNF
21 regulation of synapse organization GO:0050807 9.78 IL10 IL10RA TNF
22 positive regulation of glial cell proliferation GO:0060252 9.77 IL6 LTA TNF
23 positive regulation of interferon-gamma production GO:0032729 9.77 FADD IL1R1 LTA SLC11A1 TNF
24 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.76 CASP8 FADD TNFRSF10A TNFSF10
25 negative regulation of growth of symbiont in host GO:0044130 9.75 IL10 LTA TNF
26 defense response to protozoan GO:0042832 9.73 IL10 SLC11A1
27 positive regulation of chemokine production GO:0032722 9.73 IL6 TNF
28 negative regulation of cardiac muscle hypertrophy GO:0010614 9.73 TNFRSF1A TNFRSF1B
29 positive regulation of proteolysis GO:0045862 9.72 CASP8 FADD
30 iron ion transport GO:0006826 9.72 B2M SLC11A1
31 lymph node development GO:0048535 9.72 FADD LTA
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF TNFRSF1B
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
34 activation of cysteine-type endopeptidase activity GO:0097202 9.71 CASP8 FADD
35 positive regulation of macrophage differentiation GO:0045651 9.71 CASP8 FADD
36 response to molecule of bacterial origin GO:0002237 9.7 B2M IL10
37 toll-like receptor 3 signaling pathway GO:0034138 9.7 CASP8 FADD
38 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
39 positive regulation of ceramide biosynthetic process GO:2000304 9.7 TNF TNFRSF1A
40 TRAIL-activated apoptotic signaling pathway GO:0036462 9.7 CASP8 FADD TNFRSF10A
41 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
42 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF TNFRSF1A
43 regulation of necroptotic process GO:0060544 9.68 CASP8 FADD
44 necroptotic signaling pathway GO:0097527 9.68 FADD TNF
45 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
46 positive regulation of neuroinflammatory response GO:0150078 9.67 IL6 TNF
47 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.66 LTA TNF
48 aortic valve development GO:0003176 9.65 TNFRSF1A TNFRSF1B
49 negative regulation of extracellular matrix constituent secretion GO:0003332 9.65 TNFRSF1A TNFRSF1B
50 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.64 TNFRSF1A TNFRSF1B

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 death receptor binding GO:0005123 9.46 CASP8 FADD
2 protease binding GO:0002020 9.46 FADD IL1R1 TNF TNFRSF10A
3 tumor necrosis factor-activated receptor activity GO:0005031 9.43 TNFRSF1A TNFRSF1B
4 cytokine activity GO:0005125 9.43 IL10 IL1A IL6 LTA TNF TNFSF10
5 tumor necrosis factor receptor superfamily binding GO:0032813 9.4 FADD TNFSF10
6 TRAIL binding GO:0045569 9.37 TNFRSF10A TNFSF10
7 death effector domain binding GO:0035877 9.32 CASP8 FADD
8 tumor necrosis factor binding GO:0043120 9.26 TNFRSF1A TNFRSF1B
9 tumor necrosis factor receptor binding GO:0005164 9.02 CASP8 FADD LTA TNF TNFSF10

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....